Patients with advanced breast cancer who are treated with a combination of drugs are at increased risk of suffering adverse side effects...
List view / Grid view
Filter the results
Data show Roche’s new subcutaneous form of Herceptin is preferred by patients and could save resources in Europe’s hospitals
30 September 2013 | By Roche
Use of new Herceptin formulation reduced the time needed for pharmacists and doctors to treat patients...
Roche’s new timesaving formulation of Herceptin approved in Europe for the treatment of HER2-positive breast cancer
2 September 2013 | By Roche
Roche announced that a new injectable (subcutaneous) formulation of Herceptin (trastuzumab) has been approved by the European Commission...
28 June 2013 | By Roche
"Over the last 14 years, Herceptin has revolutionised the treatment of HER2-positive breast cancer..."
18 April 2013 | By Pedro R. Cutillas, MRC Clinical Sciences Centre, Imperial College London
Not all cancer patients, even those with the same tumour type, respond to therapy equally well. An understanding of this heterogeneity at the molecular level is crucial for further advances in the development of cancer therapies. Discerning the mechanisms of cancer heterogeneity will lead to a better selection of the…